http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110840836-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18
filingDate 2019-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2021-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2021-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-110840836-B
titleOfInvention Benzamide compound IMB16-4 nano suspension and preparation method thereof
abstract The invention discloses a benzamide compound IMB16-4 nano suspension and a preparation method thereof, wherein the IMB16-4 nano suspension comprises: bulk drug IMB16-4 and stabilizer; the stabilizing agent comprises one or more of hydrophilic materials and phospholipids; the preparation method comprises the following steps: weighing bulk drug IMB16-4 and stabilizer; dissolving a bulk drug IMB16-4 in a good solvent, then dripping the solution into a water solvent containing a stabilizer, and magnetically stirring to obtain milky suspension; centrifuging the suspension, taking a precipitate, and adding the precipitate into another part of water solvent containing a stabilizing agent for dispersion; carrying out ultrasonic crushing on the dispersed solution to obtain IMB16-4 nano suspension; the IMB16-4 nanosuspension was freeze-dried. The nanosuspension can remarkably improve the solubility, dissolution rate and bioavailability of an insoluble bulk drug IMB 16-4; and the nano suspension has large drug content, so that the dosage and times of drug administration can be reduced, adverse reactions are reduced, the drug safety is improved, and the nano suspension has good drug forming property.
priorityDate 2019-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394623
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO01945
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID679
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538066
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962

Total number of triples: 26.